National Mutual Insurance Federation Of Agricultural Cooperatives Decreased By $442,500 Its Netflix (NFLX) Position; Glycomimetics (GLYC) Shorts Increased By 31.9%

June 14, 2018 - By George Granger

Netflix, Inc. (NASDAQ:NFLX) Logo

National Mutual Insurance Federation Of Agricultural Cooperatives decreased Netflix Inc (NFLX) stake by 12.93% reported in 2018Q1 SEC filing. National Mutual Insurance Federation Of Agricultural Cooperatives sold 1,500 shares as Netflix Inc (NFLX)’s stock rose 19.42%. The National Mutual Insurance Federation Of Agricultural Cooperatives holds 10,100 shares with $2.98M value, down from 11,600 last quarter. Netflix Inc now has $171.25 billion valuation. The stock increased 3.69% or $14.0225 during the last trading session, reaching $393.9525. About 11.71M shares traded or 25.07% up from the average. Netflix, Inc. (NASDAQ:NFLX) has risen 115.45% since June 14, 2017 and is uptrending. It has outperformed by 102.88% the S&P500. Some Historical NFLX News: ; 09/03/2018 – Can Disney Stop Netflix? — Barrons.com; 13/04/2018 – COMCAST CORP – NETFLIX-RELATED BILLING WILL BE HANDLED DIRECTLY BY COMCAST; 13/03/2018 – For Disney, the answer appears to be over the top content (OTT), an option it announced as it pulled its movies and shows from Netflix last year; 13/04/2018 – COMCAST CORP – COMCAST TO OFFER NEW AND INNOVATIVE XFINITY PACKAGES INCLUDING NETFLIX SUBSCRIPTION; 01/05/2018 – EINHORN: HIS SHORT ON NETFLIX, LONG ON GM, WERE BIGGEST LOSERS; 31/05/2018 – Google and Netflix Buying up Massive Quantities of Helium; 13/03/2018 – Variety: Netflix Takes International VOD Rights to Mateo Gil’s `Thermodynamics’; 12/03/2018 – CITRON SAYS NETFLIX’S CONTENT SPEND “UNSUSTAINABLE LONG TERM” – TWEET; 21/05/2018 – CNN Money: Obamas will be on and off camera in unique Netflix deal; 06/04/2018 – Lost in Space, Netflix – absurdly contrived, yet gripping

Glycomimetics Inc (NASDAQ:GLYC) had an increase of 31.9% in short interest. GLYC’s SI was 5.94M shares in June as released by FINRA. Its up 31.9% from 4.50M shares previously. With 1.36M avg volume, 4 days are for Glycomimetics Inc (NASDAQ:GLYC)’s short sellers to cover GLYC’s short positions. The SI to Glycomimetics Inc’s float is 26.18%. The stock decreased 5.09% or $0.89 during the last trading session, reaching $16.6. About 516,212 shares traded. GlycoMimetics, Inc. (NASDAQ:GLYC) has risen 27.86% since June 14, 2017 and is uptrending. It has outperformed by 15.29% the S&P500. Some Historical GLYC News: ; 19/03/2018 – GLYCOMIMETICS -TO USE PROCEEDS OF OFFERING TO CONDUCT PHASE 3 CLINICAL DEVELOPMENT PROGRAM FOR GMI-1271 IN PATIENTS WITH ACUTE MYELOID LEUKEMIA; 03/05/2018 – GLYCOMIMETICS QTR END CASH $242.6M ON FINANCING; 05/03/2018 – GlycoMimetics Announces Design of Phase 3 Clinical Trial for GMI-1271 in Relapsed/Refractory AML; 06/03/2018 – GlycoMimetics 4Q Loss/Shr 27c; 05/03/2018 – GLYCOMIMETICS TO USE OS AS PRIMARY ENDPOINT, SEES RESULTS 4Q’20; 05/03/2018 – GLYCOMIMETICS INC – MULTIPLE CLINICAL READOUTS PLANNED STARTING YEAR-END 2018 AND THROUGH 2019 AND 2020; 06/03/2018 – GLYCOMIMETICS REPORTS 4Q & YEAR-END 2017 RESULTS; 30/05/2018 – GLYCOMIMETICS INC – ANNOUNCED THAT GENERIC NAME FOR GMI-1271 WILL BE UPROLESELAN; 05/03/2018 – GLYCOMIMETICS INC – IN EARLY 2019, ANTICIPATE TOPLINE DATA FROM PROOF-OF-CONCEPT TRIAL OF GMI-1271 IN MULTIPLE MYELOMA; 06/03/2018 – GLYCOMIMETICS INC – AS OF DEC 31, 2017, HAD CASH AND CASH EQUIVALENTS OF $123.9 MLN AS COMPARED TO $40.0 MLN AS OF DECEMBER 31, 2016

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company has market cap of $705.36 million. The firm is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It currently has negative earnings. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors.

Another recent and important GlycoMimetics, Inc. (NASDAQ:GLYC) news was published by Businesswire.com which published an article titled: “GlycoMimetics to Present at Jefferies 2018 Global Healthcare Conference” on June 01, 2018.

Among 5 analysts covering GlycoMimetics (NASDAQ:GLYC), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. GlycoMimetics had 17 analyst reports since August 10, 2015 according to SRatingsIntel. On Monday, August 15 the stock rating was initiated by Cowen & Co with “Outperform”. The rating was initiated by Roth Capital with “Buy” on Monday, October 23. Stifel Nicolaus maintained GlycoMimetics, Inc. (NASDAQ:GLYC) rating on Wednesday, March 7. Stifel Nicolaus has “Buy” rating and $25 target. Jefferies maintained the stock with “Buy” rating in Tuesday, December 12 report. The firm earned “Buy” rating on Tuesday, July 26 by SunTrust. The stock has “Buy” rating by Jefferies on Friday, July 7. Jefferies maintained it with “Buy” rating and $1600 target in Monday, June 5 report. On Tuesday, September 12 the stock rating was maintained by Jefferies with “Buy”. The stock of GlycoMimetics, Inc. (NASDAQ:GLYC) earned “Buy” rating by Cowen & Co on Tuesday, June 6. Zacks upgraded GlycoMimetics, Inc. (NASDAQ:GLYC) on Monday, August 10 to “Hold” rating.

Since May 10, 2018, it had 0 insider purchases, and 6 insider sales for $1.20 million activity. 9,539 shares valued at $169,890 were sold by BARRETT M JAMES on Thursday, May 10. $169,890 worth of stock was sold by NEW ENTERPRISE ASSOCIATES 10 L P on Thursday, May 10. On Monday, June 11 Hahn Brian M. sold $348,984 worth of GlycoMimetics, Inc. (NASDAQ:GLYC) or 19,345 shares. SANDELL SCOTT D sold $169,890 worth of stock or 9,539 shares. 9,539 shares valued at $169,890 were sold by BARRIS PETER J on Thursday, May 10.

Investors sentiment decreased to 1.63 in 2018 Q1. Its down 0.87, from 2.5 in 2017Q4. It turned negative, as 17 investors sold GlycoMimetics, Inc. shares while 15 reduced holdings. 25 funds opened positions while 27 raised stakes. 42.95 million shares or 38.92% more from 30.92 million shares in 2017Q4 were reported. Baker Bros Advsr L P owns 563,312 shares for 0.08% of their portfolio. Point72 Asset Lp stated it has 0.01% in GlycoMimetics, Inc. (NASDAQ:GLYC). Morgan Stanley, New York-based fund reported 11,074 shares. Blackrock Inc holds 0% in GlycoMimetics, Inc. (NASDAQ:GLYC) or 1.19M shares. Massachusetts-based Geode Cap Mgmt Limited Co has invested 0% in GlycoMimetics, Inc. (NASDAQ:GLYC). Price T Rowe Assocs Inc Md accumulated 2.87M shares. D E Shaw And Inc reported 10,878 shares stake. The Alabama-based Weiss Multi has invested 0.02% in GlycoMimetics, Inc. (NASDAQ:GLYC). Financial Bank Of Mellon reported 0% stake. 66,379 were accumulated by Citigroup. Daiwa Secs Grp Inc reported 0% of its portfolio in GlycoMimetics, Inc. (NASDAQ:GLYC). Manufacturers Life Insurance The holds 0% or 1,021 shares in its portfolio. Nea Management Ltd Liability has invested 6.2% in GlycoMimetics, Inc. (NASDAQ:GLYC). Northern Tru reported 84,511 shares or 0% of all its holdings. Moreover, Proshare Advsrs Limited Liability has 0% invested in GlycoMimetics, Inc. (NASDAQ:GLYC).

Since December 18, 2017, it had 0 buys, and 48 selling transactions for $193.78 million activity. BARTON RICHARD N had sold 700 shares worth $147,886 on Monday, January 8. WELLS DAVID B sold $363,000 worth of Netflix, Inc. (NASDAQ:NFLX) on Friday, June 1. $2.77 million worth of stock was sold by BATTLE A GEORGE on Tuesday, February 13. KILGORE LESLIE J sold $471,195 worth of stock or 1,309 shares. $24.53 million worth of Netflix, Inc. (NASDAQ:NFLX) was sold by HASTINGS REED on Monday, April 23. SARANDOS THEODORE A had sold 163,747 shares worth $43.05 million on Thursday, February 8. $1.92M worth of Netflix, Inc. (NASDAQ:NFLX) was sold by Peters Gregory K.

Analysts await Netflix, Inc. (NASDAQ:NFLX) to report earnings on July, 16. They expect $0.80 earnings per share, up 433.33% or $0.65 from last year’s $0.15 per share. NFLX’s profit will be $347.75M for 123.11 P/E if the $0.80 EPS becomes a reality. After $0.64 actual earnings per share reported by Netflix, Inc. for the previous quarter, Wall Street now forecasts 25.00% EPS growth.

Investors sentiment decreased to 1.23 in Q1 2018. Its down 0.08, from 1.31 in 2017Q4. It fall, as 47 investors sold NFLX shares while 310 reduced holdings. 156 funds opened positions while 283 raised stakes. 329.43 million shares or 4.36% less from 344.43 million shares in 2017Q4 were reported. American Century Cos holds 0.28% or 932,272 shares in its portfolio. Moreover, Janney Montgomery Scott Ltd Com has 0.13% invested in Netflix, Inc. (NASDAQ:NFLX) for 45,252 shares. Acg Wealth holds 1.15% of its portfolio in Netflix, Inc. (NASDAQ:NFLX) for 25,632 shares. Hoertkorn Richard Charles accumulated 55 shares. Waldron LP holds 0.09% or 1,414 shares. Regions Fincl reported 6,019 shares or 0.02% of all its holdings. Optimum Inv holds 0.13% of its portfolio in Netflix, Inc. (NASDAQ:NFLX) for 1,450 shares. Missouri-based Stifel Financial Corp has invested 0.12% in Netflix, Inc. (NASDAQ:NFLX). Swiss Bank invested in 0.5% or 1.39 million shares. Amp Limited holds 160,320 shares or 0.26% of its portfolio. Segment Wealth Management Lc, a Texas-based fund reported 1,485 shares. Evermay Wealth Mgmt Limited Liability Corporation holds 0.22% of its portfolio in Netflix, Inc. (NASDAQ:NFLX) for 2,130 shares. Oakbrook Investments Lc reported 4,745 shares. Brighton Jones Lc invested 0.59% in Netflix, Inc. (NASDAQ:NFLX). Burns J W reported 1.6% of its portfolio in Netflix, Inc. (NASDAQ:NFLX).

More notable recent Netflix, Inc. (NASDAQ:NFLX) news were published by: Benzinga.com which released: “Citron Says Netflix Bulls Need A ‘Reality Check'” on June 14, 2018, also Seekingalpha.com with their article: “No One Is Buying Netflix” published on June 14, 2018, Benzinga.com published: “Goldman Sachs Raises Netflix Price Target To $490, Projects Positive Cash Flow By 2022” on June 13, 2018. More interesting news about Netflix, Inc. (NASDAQ:NFLX) were released by: Fool.com and their article: “Netflix’s First Comic Book Is Poised to Break a 20-Year-Old Record” published on June 14, 2018 as well as Nasdaq.com‘s news article titled: “Here’s How Netflix Made Warner Bros. Television Fork Over $300 Million” with publication date: June 14, 2018.

Among 58 analysts covering Netflix (NASDAQ:NFLX), 39 have Buy rating, 2 Sell and 17 Hold. Therefore 67% are positive. Netflix had 263 analyst reports since August 4, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets with “Market Perform” on Tuesday, October 17. The company was maintained on Friday, June 16 by RBC Capital Markets. The stock has “Hold” rating by SunTrust on Tuesday, October 18. The stock of Netflix, Inc. (NASDAQ:NFLX) has “Buy” rating given on Tuesday, July 18 by Pivotal Research. Credit Suisse maintained the stock with “Neutral” rating in Monday, April 18 report. The stock has “Neutral” rating by Robert W. Baird on Tuesday, April 19. The company was maintained on Tuesday, January 23 by Bernstein. Jefferies maintained the stock with “Hold” rating in Friday, October 6 report. The firm has “Overweight” rating by JP Morgan given on Tuesday, April 19. On Tuesday, April 17 the stock rating was maintained by FBR Capital with “Hold”.

Netflix, Inc. (NASDAQ:NFLX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: